Veterinary Vaccine Market By Type (Beef , Equine, Dairy , Pork , Poultry , Sheep, Dog, Feline, Swine, Aquaculture, Ruminants, Others); By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other Vaccines); By Disease Indication (Rabies, Canine Distemper Virus (CDV), Canine Parvovirus (CPV), Canine Adenovirus (CAV), Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Spain, Germany, Italy, Nordic Countries , Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia), Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028
Industry Trends
Animal husbandry is a notable industry under the farming sector. The original applications of the products procured through the industry have been related to the food industry. With advancements in food processing and the awareness regarding the applications of the various forms of livestock across numerous sectors have increased the expanse of the industry. This has improved the understanding among investors and cultivators to look towards the industry as a lucrative option. These factors led to increasing investments in the sector, thereby, propelling the concept of animal herding for commercial applications. With the growth in the sector, there was an observation related to various diseases which were contacted by numerous animals. This created a potential risk for the herders and subsequently for the investors in the sector. Veterinary medicine has been vital in reducing these risks through the development of medication and vaccines across various forms of animals used in the industry. Growing prevalence of newer forms of diseases have provided impetus for increased investments towards the research and development of vaccines in the veterinary medicine sector. The integration of initiatives from governing authorities encouraging the development of newer veterinary vaccines and the positive adoption trend among users is expected to help the growth of the market in the coming years. In addition to this, innovative marketing initiatives from market participants are hopeful to provide them access to a wider consumer base. These efforts are expected to provide the market with more users, thereby, ensuring revenue growth over the near future.
The burden of infectious diseases in livestock and other animals continues to be a major constraint on the economic benefits of international trade in livestock commodities for sustainable agricultural production, food security and participation of developing and transition countries. In order to minimise the prevalence of infectious diseases targeted steps must be adopted in countries where there is a prevalence of infectious diseases. Vaccination programmes must be undertaken in order to minimize the spread of infectious disease on livestock and other animals. Increased demand for livestock products driven by population growth, increased urbanisation and higher individual buying power in developing or middle-income countries are some of the factors boosting the growth of veterinary market over the forecast period. Recent assessments suggest that infectious diseases will continue to constitute a major constraint on sustained foreign exports of livestock products from developed countries unless targeted steps are taken to reduce the burden of infectious diseases in those countries. Vaccination has been considered one of the most important sanitary steps for the prevention, control and eradication of infectious diseases in domestic and wild animals and one of the reasons available to counter the growing demand for food supplies and food dependence. Compared to vaccines intended for human use, the cost-benefit balance for both farmers and industry is the primary factor deciding the development and practical use of veterinary vaccines. Vaccines with low development costs eliminates zoo sanitary risks, efficiency and expense restrictions in clinical practise and also the production of these vaccines can be afforded by manufacturers thus boosting the growth of veterinary vaccines market over the forecast period. Livestock diseases are leading to a number of problems, these challenges include decline in production, unstable food security and loss of income, and these factors are adversely affecting human health. Vaccination assists in management of livestock diseases and minimise illness by vaccinating animals. The market for veterinary vaccines is vibrant with players introducing policies for biological and inorganic production to amplify their product offerings, strengthen their global distribution and increase consumer reach which will in turn boost the development of veterinary vaccines.
The global veterinary vaccine market was estimated to be US$ 7.89 Mn in 2019 and is expected to reach US$ 13.97 by 2028, growing at an estimated CAGR of 7.5% over the forecast period.
By Type
The presence of various types of livestock in the animal husbandry sector have been mainly due to the numerous applications of products manufactured through the industry coupled with the focus on the healthcare of livestock. Notable forms of livestock observed across various regions include bovines, poultry, swine and pigs among others. The numbers for the livestock are expected to grow year over year thereby providing significant demand for the market offerings. The growing prevalence of numerous diseases have been vital in focusing the efforts of market participants towards product development and supply chain optimization for proper supply of existing offerings. These factors are expected to aid the growth of the revenue generated in the market.
By Technology
Numerous technologies are used in the development of vaccines used in veterinary applications. Depending on the disease being acted upon, the type of technology for the vaccine changes. The changes in the technology are also seen to be dependent on the animal that is expected to be administered with the final vaccine. Major vaccine technologies observed in the market include live attenuated vaccines, inactivated vaccines, toxoid vaccines, and recombinant vaccines, among others. Live attenuated vaccines deal with the type of vaccines which contain the weakened form of the organism which leads to the development of diseases in animals. This helps in creation of better immune responses from the animal’s body and helps in mitigating potential risks for the future. Toxoid vaccines contain toxic forms of the virus or allied organism which is reacted upon through the immune system of animal’s body. This helps the body in creating similar responses when encountering such organisms in the future thereby, safeguarding the body from potential risks. The vaccines are growing in terms of prominence owing to focus on development of newer technologies in their creation along with the form of delivery in the animals.
By Disease Indication
Notable diseases that have affected animals of various forms include rabies and viral disorders among others. The growing prevalence of the forms of diseases has alarmed governing authorities to encourage private and public entities towards the formation of vaccines over the years. These efforts are expected to aid livestock in tackling future risks to their health through the adoption of veterinary vaccines across various regions.
By Region
The presence of livestock is important across various regions for the products to be developed in future. Major presence of livestock is observed across regions including Asia Pacific, North America, and South America, among others. This creates a demand for various products and services that help in the enhancement and healthcare of livestock. The growing prevalence of diseases has led caretakers to look towards innovative ways to safeguard their livestock. Veterinary vaccines are targeted as a safety mechanism for livestock and are being significantly adopted across various countries. North America has been a major proponent for the market owing to the abundance of animal life in the region. In addition to this, higher marketing focus from market participants along with dedicated initiatives towards product development to ensure longer product lines and service life is expected to aid the growth of the market over the forecast period. Asia Pacific is another region with high presence of livestock owing to the various applications of products based on animal husbandry in the region. Furthermore, increasing investments in the sector is expected to spur the demand for various products and services allied to the industry. The growing agriculture and food processing sector in the region are also expected to aid the demand for livestock safety products across the region. These factors are expected to aid the growth of the market on the global scale across the forecast period.
Veterinary Vaccine Market Revenue & Forecast, (US$ Million), 2015 – 2028
Competitive Landscape
The report provides both, qualitative and quantitative research of veterinary vaccine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The major players operating in the veterinary vaccine market include Aptimmune Biologics Inc., Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private Limited, Ceva, China Animal Husbandry, Covetrus, Elanco, Hester Biosciences Limited., Merck & Co. Inc. (Intervet International B.V.), Torigen, VEROVACCiNES GmbH. Vetoquinol S.A., Virbac, Zoetis and other market participants.
Veterinary Vaccine Market:
- By Type
- Beef
- Equine
- Dairy
- Pork
- Poultry
- Sheep
- Dog
- Feline
- Swine
- Aquaculture
- Ruminants
- Others
- By Technology
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Other Vaccines
- By Disease Indication
- Rabies
- Canine Distemper Virus (CDV)
- Canine Parvovirus (CPV)
- Canine Adenovirus (CAV)
- Others
- By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Veterinary Vaccine Market
6. Market
Synopsis: Veterinary Vaccine Market
7. Veterinary
Vaccine Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Veterinary Vaccine Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Veterinary Vaccine Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Veterinary Vaccine Market
8. Global
Veterinary Vaccine Market Analysis and Forecasts, 2020 – 2028
8.1. Overview
8.1.1. Global
Veterinary Vaccine Market Revenue (US$ Mn)
8.2. Global
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Beef
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2019
8.2.1.3. Market
Forecast, 2020 – 2028
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2019
8.2.1.5.1.2. Market
Forecast, 2020 – 2028
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2019
8.2.1.5.2.2. Market
Forecast, 2020 – 2028
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2019
8.2.1.5.3.2. Market
Forecast, 2020 – 2028
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2019
8.2.1.5.4.2. Market
Forecast, 2020 – 2028
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2019
8.2.1.5.5.2. Market
Forecast, 2020 – 2028
8.2.2. Equine
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2019
8.2.2.3. Market
Forecast, 2020 – 2028
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2019
8.2.2.5.1.2. Market
Forecast, 2020 – 2028
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2019
8.2.2.5.2.2. Market
Forecast, 2020 – 2028
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2019
8.2.2.5.3.2. Market
Forecast, 2020 – 2028
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2019
8.2.2.5.4.2. Market
Forecast, 2020 – 2028
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2019
8.2.2.5.5.2. Market
Forecast, 2020 – 2028
8.2.3. Dairy
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2019
8.2.3.3. Market
Forecast, 2020 – 2028
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2019
8.2.3.5.1.2. Market
Forecast, 2020 – 2028
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2019
8.2.3.5.2.2. Market
Forecast, 2020 – 2028
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2019
8.2.3.5.3.2. Market
Forecast, 2020 – 2028
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2019
8.2.3.5.4.2. Market
Forecast, 2020 – 2028
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2019
8.2.3.5.5.2. Market
Forecast, 2020 – 2028
8.2.4. Pork
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2015 – 2019
8.2.4.3. Market
Forecast, 2020 – 2028
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 – 2019
8.2.4.5.1.2. Market
Forecast, 2020 – 2028
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 – 2019
8.2.4.5.2.2. Market
Forecast, 2020 – 2028
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 – 2019
8.2.4.5.3.2. Market
Forecast, 2020 – 2028
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 – 2019
8.2.4.5.4.2. Market
Forecast, 2020 – 2028
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 – 2019
8.2.4.5.5.2. Market
Forecast, 2020 – 2028
8.2.5. Poultry
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2015 – 2019
8.2.5.3. Market
Forecast, 2020 – 2028
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2015 – 2019
8.2.5.5.1.2. Market
Forecast, 2020 – 2028
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 – 2019
8.2.5.5.2.2. Market
Forecast, 2020 – 2028
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2015 – 2019
8.2.5.5.3.2. Market
Forecast, 2020 – 2028
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 – 2019
8.2.5.5.4.2. Market
Forecast, 2020 – 2028
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2015 – 2019
8.2.5.5.5.2. Market
Forecast, 2020 – 2028
8.2.6. Sheep
8.2.6.1. Definition
8.2.6.2. Market
Estimation and Penetration, 2015 – 2019
8.2.6.3. Market
Forecast, 2020 – 2028
8.2.6.4. Compound
Annual Growth Rate (CAGR)
8.2.6.5. Regional
Bifurcation
8.2.6.5.1. North
America
8.2.6.5.1.1. Market
Estimation, 2015 – 2019
8.2.6.5.1.2. Market
Forecast, 2020 – 2028
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 – 2019
8.2.6.5.2.2. Market
Forecast, 2020 – 2028
8.2.6.5.3. Asia
Pacific
8.2.6.5.3.1. Market
Estimation, 2015 – 2019
8.2.6.5.3.2. Market
Forecast, 2020 – 2028
8.2.6.5.4. Middle
East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 – 2019
8.2.6.5.4.2. Market
Forecast, 2020 – 2028
8.2.6.5.5. Latin
America
8.2.6.5.5.1. Market
Estimation, 2015 – 2019
8.2.6.5.5.2. Market
Forecast, 2020 – 2028
8.2.7. Dog
8.2.7.1. Definition
8.2.7.2. Market
Estimation and Penetration, 2015 – 2019
8.2.7.3. Market
Forecast, 2020 – 2028
8.2.7.4. Compound
Annual Growth Rate (CAGR)
8.2.7.5. Regional
Bifurcation
8.2.7.5.1. North
America
8.2.7.5.1.1. Market
Estimation, 2015 – 2019
8.2.7.5.1.2. Market
Forecast, 2020 – 2028
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2015 – 2019
8.2.7.5.2.2. Market
Forecast, 2020 – 2028
8.2.7.5.3. Asia
Pacific
8.2.7.5.3.1. Market
Estimation, 2015 – 2019
8.2.7.5.3.2. Market
Forecast, 2020 – 2028
8.2.7.5.4. Middle
East and Africa
8.2.7.5.4.1. Market
Estimation, 2015 – 2019
8.2.7.5.4.2. Market
Forecast, 2020 – 2028
8.2.7.5.5. Latin
America
8.2.7.5.5.1. Market
Estimation, 2015 – 2019
8.2.7.5.5.2. Market
Forecast, 2020 – 2028
8.2.8. Feline
8.2.8.1. Definition
8.2.8.2. Market
Estimation and Penetration, 2015 – 2019
8.2.8.3. Market
Forecast, 2020 – 2028
8.2.8.4. Compound
Annual Growth Rate (CAGR)
8.2.8.5. Regional
Bifurcation
8.2.8.5.1. North
America
8.2.8.5.1.1. Market
Estimation, 2015 – 2019
8.2.8.5.1.2. Market
Forecast, 2020 – 2028
8.2.8.5.2. Europe
8.2.8.5.2.1. Market
Estimation, 2015 – 2019
8.2.8.5.2.2. Market
Forecast, 2020 – 2028
8.2.8.5.3. Asia
Pacific
8.2.8.5.3.1. Market
Estimation, 2015 – 2019
8.2.8.5.3.2. Market
Forecast, 2020 – 2028
8.2.8.5.4. Middle
East and Africa
8.2.8.5.4.1. Market
Estimation, 2015 – 2019
8.2.8.5.4.2. Market
Forecast, 2020 – 2028
8.2.8.5.5. Latin
America
8.2.8.5.5.1. Market
Estimation, 2015 – 2019
8.2.8.5.5.2. Market
Forecast, 2020 – 2028
8.2.9. Swine
8.2.9.1. Definition
8.2.9.2. Market
Estimation and Penetration, 2015 – 2019
8.2.9.3. Market
Forecast, 2020 – 2028
8.2.9.4. Compound
Annual Growth Rate (CAGR)
8.2.9.5. Regional
Bifurcation
8.2.9.5.1. North
America
8.2.9.5.1.1. Market
Estimation, 2015 – 2019
8.2.9.5.1.2. Market
Forecast, 2020 – 2028
8.2.9.5.2. Europe
8.2.9.5.2.1. Market
Estimation, 2015 – 2019
8.2.9.5.2.2. Market
Forecast, 2020 – 2028
8.2.9.5.3. Asia
Pacific
8.2.9.5.3.1. Market
Estimation, 2015 – 2019
8.2.9.5.3.2. Market
Forecast, 2020 – 2028
8.2.9.5.4. Middle
East and Africa
8.2.9.5.4.1. Market
Estimation, 2015 – 2019
8.2.9.5.4.2. Market
Forecast, 2020 – 2028
8.2.9.5.5. Latin
America
8.2.9.5.5.1. Market
Estimation, 2015 – 2019
8.2.9.5.5.2. Market
Forecast, 2020 – 2028
8.2.10. Aquaculture
8.2.10.1. Definition
8.2.10.2. Market
Estimation and Penetration, 2015 – 2019
8.2.10.3. Market
Forecast, 2020 – 2028
8.2.10.4. Compound
Annual Growth Rate (CAGR)
8.2.10.5. Regional
Bifurcation
8.2.10.5.1. North
America
8.2.10.5.1.1. Market
Estimation, 2015 – 2019
8.2.10.5.1.2. Market
Forecast, 2020 – 2028
8.2.10.5.2. Europe
8.2.10.5.2.1. Market
Estimation, 2015 – 2019
8.2.10.5.2.2. Market
Forecast, 2020 – 2028
8.2.10.5.3. Asia
Pacific
8.2.10.5.3.1. Market
Estimation, 2015 – 2019
8.2.10.5.3.2. Market
Forecast, 2020 – 2028
8.2.10.5.4. Middle
East and Africa
8.2.10.5.4.1. Market
Estimation, 2015 – 2019
8.2.10.5.4.2. Market
Forecast, 2020 – 2028
8.2.10.5.5. Latin
America
8.2.10.5.5.1. Market
Estimation, 2015 – 2019
8.2.10.5.5.2. Market
Forecast, 2020 – 2028
8.2.11. Ruminants
8.2.11.1. Definition
8.2.11.2. Market
Estimation and Penetration, 2015 – 2019
8.2.11.3. Market
Forecast, 2020 – 2028
8.2.11.4. Compound
Annual Growth Rate (CAGR)
8.2.11.5. Regional
Bifurcation
8.2.11.5.1. North
America
8.2.11.5.1.1. Market
Estimation, 2015 – 2019
8.2.11.5.1.2. Market
Forecast, 2020 – 2028
8.2.11.5.2. Europe
8.2.11.5.2.1. Market
Estimation, 2015 – 2019
8.2.11.5.2.2. Market
Forecast, 2020 – 2028
8.2.11.5.3. Asia
Pacific
8.2.11.5.3.1. Market
Estimation, 2015 – 2019
8.2.11.5.3.2. Market
Forecast, 2020 – 2028
8.2.11.5.4. Middle
East and Africa
8.2.11.5.4.1. Market
Estimation, 2015 – 2019
8.2.11.5.4.2. Market
Forecast, 2020 – 2028
8.2.11.5.5. Latin
America
8.2.11.5.5.1. Market
Estimation, 2015 – 2019
8.2.11.5.5.2. Market
Forecast, 2020 – 2028
8.2.12. Others
8.2.12.1. Definition
8.2.12.2. Market
Estimation and Penetration, 2015 – 2019
8.2.12.3. Market
Forecast, 2020 – 2028
8.2.12.4. Compound
Annual Growth Rate (CAGR)
8.2.12.5. Regional
Bifurcation
8.2.12.5.1. North
America
8.2.12.5.1.1. Market
Estimation, 2015 – 2019
8.2.12.5.1.2. Market
Forecast, 2020 – 2028
8.2.12.5.2. Europe
8.2.12.5.2.1. Market
Estimation, 2015 – 2019
8.2.12.5.2.2. Market
Forecast, 2020 – 2028
8.2.12.5.3. Asia
Pacific
8.2.12.5.3.1. Market
Estimation, 2015 – 2019
8.2.12.5.3.2. Market
Forecast, 2020 – 2028
8.2.12.5.4. Middle
East and Africa
8.2.12.5.4.1. Market
Estimation, 2015 – 2019
8.2.12.5.4.2. Market
Forecast, 2020 – 2028
8.2.12.5.5. Latin
America
8.2.12.5.5.1. Market
Estimation, 2015 – 2019
8.2.12.5.5.2. Market
Forecast, 2020 – 2028
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global
Veterinary Vaccine Market Analysis and Forecasts, 2020 – 2028
9.1. Overview
9.2. Global
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
9.2.1. Live
Attenuated Vaccines
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2019
9.2.1.3. Market
Forecast, 2020 – 2028
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2019
9.2.1.5.1.2. Market
Forecast, 2020 – 2028
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2019
9.2.1.5.2.2. Market
Forecast, 2020 – 2028
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2019
9.2.1.5.3.2. Market
Forecast, 2020 – 2028
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2019
9.2.1.5.4.2. Market
Forecast, 2020 – 2028
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2019
9.2.1.5.5.2. Market
Forecast, 2020 – 2028
9.2.2. Inactivated
Vaccines
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2019
9.2.2.3. Market
Forecast, 2020 – 2028
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2019
9.2.2.5.1.2. Market
Forecast, 2020 – 2028
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2019
9.2.2.5.2.2. Market
Forecast, 2020 – 2028
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2019
9.2.2.5.3.2. Market
Forecast, 2020 – 2028
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2019
9.2.2.5.4.2. Market
Forecast, 2020 – 2028
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2019
9.2.2.5.5.2. Market
Forecast, 2020 – 2028
9.2.3. Toxoid
Vaccines
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2019
9.2.3.3. Market
Forecast, 2020 – 2028
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2019
9.2.3.5.1.2. Market
Forecast, 2020 – 2028
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2019
9.2.3.5.2.2. Market
Forecast, 2020 – 2028
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2019
9.2.3.5.3.2. Market
Forecast, 2020 – 2028
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2019
9.2.3.5.4.2. Market
Forecast, 2020 – 2028
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2019
9.2.3.5.5.2. Market
Forecast, 2020 – 2028
9.2.4. Recombinant
Vaccines
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 – 2019
9.2.4.3. Market
Forecast, 2020 – 2028
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 – 2019
9.2.4.5.1.2. Market
Forecast, 2020 – 2028
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2019
9.2.4.5.2.2. Market
Forecast, 2020 – 2028
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2019
9.2.4.5.3.2. Market
Forecast, 2020 – 2028
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2019
9.2.4.5.4.2. Market
Forecast, 2020 – 2028
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 – 2019
9.2.4.5.5.2. Market
Forecast, 2020 – 2028
9.2.5. Other
Vaccines
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 – 2019
9.2.5.3. Market
Forecast, 2020 – 2028
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 – 2019
9.2.5.5.1.2. Market
Forecast, 2020 – 2028
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 – 2019
9.2.5.5.2.2. Market
Forecast, 2020 – 2028
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 – 2019
9.2.5.5.3.2. Market
Forecast, 2020 – 2028
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 – 2019
9.2.5.5.4.2. Market
Forecast, 2020 – 2028
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 – 2019
9.2.5.5.5.2. Market
Forecast, 2020 – 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By
Technology
10. Global
Veterinary Vaccine Market Analysis and Forecasts, 2020 – 2028
10.1. Overview
10.2. Global
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
10.2.1. Rabies
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2019
10.2.1.3. Market
Forecast, 2020 – 2028
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2019
10.2.1.5.1.2. Market
Forecast, 2020 – 2028
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2019
10.2.1.5.2.2. Market
Forecast, 2020 – 2028
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2019
10.2.1.5.3.2. Market
Forecast, 2020 – 2028
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2019
10.2.1.5.4.2. Market
Forecast, 2020 – 2028
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2019
10.2.1.5.5.2. Market
Forecast, 2020 – 2028
10.2.2. Canine
Distemper Virus (CDV)
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2019
10.2.2.3. Market
Forecast, 2020 – 2028
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2019
10.2.2.5.1.2. Market
Forecast, 2020 – 2028
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2019
10.2.2.5.2.2. Market
Forecast, 2020 – 2028
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2019
10.2.2.5.3.2. Market
Forecast, 2020 – 2028
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2019
10.2.2.5.4.2. Market
Forecast, 2020 – 2028
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2019
10.2.2.5.5.2. Market
Forecast, 2020 – 2028
10.2.3. Canine
Parvovirus (CPV)
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2019
10.2.3.3. Market
Forecast, 2020 – 2028
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2019
10.2.3.5.1.2. Market
Forecast, 2020 – 2028
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2019
10.2.3.5.2.2. Market
Forecast, 2020 – 2028
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2019
10.2.3.5.3.2. Market
Forecast, 2020 – 2028
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2019
10.2.3.5.4.2. Market
Forecast, 2020 – 2028
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2019
10.2.3.5.5.2. Market
Forecast, 2020 – 2028
10.2.4. Canine Adenovirus (CAV)
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 – 2019
10.2.4.3. Market
Forecast, 2020 – 2028
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 – 2019
10.2.4.5.1.2. Market
Forecast, 2020 – 2028
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2019
10.2.4.5.2.2. Market
Forecast, 2020 – 2028
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2019
10.2.4.5.3.2. Market
Forecast, 2020 – 2028
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2019
10.2.4.5.4.2. Market
Forecast, 2020 – 2028
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 – 2019
10.2.4.5.5.2. Market
Forecast, 2020 – 2028
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2015 – 2019
10.2.5.3. Market
Forecast, 2020 – 2028
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2015 – 2019
10.2.5.5.1.2. Market
Forecast, 2020 – 2028
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 – 2019
10.2.5.5.2.2. Market
Forecast, 2020 – 2028
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2015 – 2019
10.2.5.5.3.2. Market
Forecast, 2020 – 2028
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 – 2019
10.2.5.5.4.2. Market
Forecast, 2020 – 2028
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2015 – 2019
10.2.5.5.5.2. Market
Forecast, 2020 – 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By
Disease Indication
11. North
America Veterinary Vaccine Market Analysis and Forecasts, 2020 - 2028
11.1. Overview
11.1.1. North
America Veterinary Vaccine Market Revenue (US$ Mn)
11.2. North
America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
11.2.1. Beef
11.2.2. Equine
11.2.3. Dairy
11.2.4. Pork
11.2.5. Poultry
11.2.6. Sheep
11.2.7. Dog
11.2.8. Feline
11.2.9. Swine
11.2.10. Aquaculture
11.2.11. Ruminants
11.2.12. Others
11.3. North
America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
11.3.1. Live
Attenuated Vaccines
11.3.2. Inactivated
Vaccines
11.3.3. Toxoid
Vaccines
11.3.4. Recombinant
Vaccines
11.3.5. Other
Vaccines
11.4. North
America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
11.4.1. Rabies
11.4.2. Canine
Distemper Virus (CDV)
11.4.3. Canine
Parvovirus (CPV)
11.4.4. Canine Adenovirus (CAV)
11.4.5. Others
11.5. North
America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
11.5.1.1.1. Beef
11.5.1.1.2. Equine
11.5.1.1.3. Dairy
11.5.1.1.4. Pork
11.5.1.1.5. Poultry
11.5.1.1.6. Sheep
11.5.1.1.7. Dog
11.5.1.1.8. Feline
11.5.1.1.9. Swine
11.5.1.1.10. Aquaculture
11.5.1.1.11. Ruminants
11.5.1.1.12. Others
11.5.1.2. U.S
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
11.5.1.2.1. Live
Attenuated Vaccines
11.5.1.2.2. Inactivated
Vaccines
11.5.1.2.3. Toxoid
Vaccines
11.5.1.2.4. Recombinant
Vaccines
11.5.1.2.5. Other
Vaccines
11.5.1.3. U.S
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.5.1.3.1. Rabies
11.5.1.3.2. Canine
Distemper Virus (CDV)
11.5.1.3.3. Canine
Parvovirus (CPV)
11.5.1.3.4. Canine Adenovirus (CAV)
11.5.1.3.5. Others
11.5.2. Canada
11.5.2.1. Canada
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
11.5.2.1.1. Beef
11.5.2.1.2. Equine
11.5.2.1.3. Dairy
11.5.2.1.4. Pork
11.5.2.1.5. Poultry
11.5.2.1.6. Sheep
11.5.2.1.7. Dog
11.5.2.1.8. Feline
11.5.2.1.9. Swine
11.5.2.1.10. Aquaculture
11.5.2.1.11. Ruminants
11.5.2.1.12. Others
11.5.2.2. Canada
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
11.5.2.2.1. Live
Attenuated Vaccines
11.5.2.2.2. Inactivated
Vaccines
11.5.2.2.3. Toxoid
Vaccines
11.5.2.2.4. Recombinant
Vaccines
11.5.2.2.5. Other
Vaccines
11.5.2.3. Canada
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.5.2.3.1. Rabies
11.5.2.3.2. Canine
Distemper Virus (CDV)
11.5.2.3.3. Canine
Parvovirus (CPV)
11.5.2.3.4. Canine Adenovirus (CAV)
11.5.2.3.5. Others
11.5.3. Mexico
11.5.3.1. Mexico
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
11.5.3.1.1. Beef
11.5.3.1.2. Equine
11.5.3.1.3. Dairy
11.5.3.1.4. Pork
11.5.3.1.5. Poultry
11.5.3.1.6. Sheep
11.5.3.1.7. Dog
11.5.3.1.8. Feline
11.5.3.1.9. Swine
11.5.3.1.10. Aquaculture
11.5.3.1.11. Ruminants
11.5.3.1.12. Others
11.5.3.2. Mexico
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
11.5.3.2.1. Live
Attenuated Vaccines
11.5.3.2.2. Inactivated
Vaccines
11.5.3.2.3. Toxoid
Vaccines
11.5.3.2.4. Recombinant
Vaccines
11.5.3.2.5. Other
Vaccines
11.5.3.3. Mexico
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.5.3.3.1. Rabies
11.5.3.3.2. Canine
Distemper Virus (CDV)
11.5.3.3.3. Canine
Parvovirus (CPV)
11.5.3.3.4. Canine Adenovirus (CAV)
11.5.3.3.5. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.4.1.1. Beef
11.5.4.1.2. Equine
11.5.4.1.3. Dairy
11.5.4.1.4. Pork
11.5.4.1.5. Poultry
11.5.4.1.6. Sheep
11.5.4.1.7. Dog
11.5.4.1.8. Feline
11.5.4.1.9. Swine
11.5.4.1.10. Aquaculture
11.5.4.1.11. Ruminants
11.5.4.1.12. Others
11.5.4.2. Rest
of North America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Technology
11.5.4.2.1. Live
Attenuated Vaccines
11.5.4.2.2. Inactivated
Vaccines
11.5.4.2.3. Toxoid
Vaccines
11.5.4.2.4. Recombinant
Vaccines
11.5.4.2.5. Other
Vaccines
11.5.4.3. Rest
of North America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
11.5.4.3.1. Rabies
11.5.4.3.2. Canine
Distemper Virus (CDV)
11.5.4.3.3. Canine
Parvovirus (CPV)
11.5.4.3.4. Canine Adenovirus (CAV)
11.5.4.3.5. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By Type
11.6.3. By
Technology
11.6.4. By
Disease Indication
12. Europe
Veterinary Vaccine Market Analysis and Forecasts, 2020 - 2028
12.1. Overview
12.1.1. Europe
Veterinary Vaccine Market Revenue (US$ Mn)
12.2. Europe
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Beef
12.2.2. Equine
12.2.3. Dairy
12.2.4. Pork
12.2.5. Poultry
12.2.6. Sheep
12.2.7. Dog
12.2.8. Feline
12.2.9. Swine
12.2.10. Aquaculture
12.2.11. Ruminants
12.2.12. Others
12.3. Europe
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
12.3.1. Live
Attenuated Vaccines
12.3.2. Inactivated
Vaccines
12.3.3. Toxoid
Vaccines
12.3.4. Recombinant
Vaccines
12.3.5. Other
Vaccines
12.4. Europe
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.4.1. Rabies
12.4.2. Canine
Distemper Virus (CDV)
12.4.3. Canine
Parvovirus (CPV)
12.4.4. Canine Adenovirus (CAV)
12.4.5. Others
12.5. Europe
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.5.1.1.1. Beef
12.5.1.1.2. Equine
12.5.1.1.3. Dairy
12.5.1.1.4. Pork
12.5.1.1.5. Poultry
12.5.1.1.6. Sheep
12.5.1.1.7. Dog
12.5.1.1.8. Feline
12.5.1.1.9. Swine
12.5.1.1.10. Aquaculture
12.5.1.1.11. Ruminants
12.5.1.1.12. Others
12.5.1.2. France
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
12.5.1.2.1. Live
Attenuated Vaccines
12.5.1.2.2. Inactivated
Vaccines
12.5.1.2.3. Toxoid
Vaccines
12.5.1.2.4. Recombinant
Vaccines
12.5.1.2.5. Other
Vaccines
12.5.1.3. France
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.1.3.1. Rabies
12.5.1.3.2. Canine
Distemper Virus (CDV)
12.5.1.3.3. Canine
Parvovirus (CPV)
12.5.1.3.4. Canine Adenovirus (CAV)
12.5.1.3.5. Others
12.5.2. The UK
12.5.2.1. The
UK Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.5.2.1.1. Beef
12.5.2.1.2. Equine
12.5.2.1.3. Dairy
12.5.2.1.4. Pork
12.5.2.1.5. Poultry
12.5.2.1.6. Sheep
12.5.2.1.7. Dog
12.5.2.1.8. Feline
12.5.2.1.9. Swine
12.5.2.1.10. Aquaculture
12.5.2.1.11. Ruminants
12.5.2.1.12. Others
12.5.2.2. The
UK Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
12.5.2.2.1. Live
Attenuated Vaccines
12.5.2.2.2. Inactivated
Vaccines
12.5.2.2.3. Toxoid
Vaccines
12.5.2.2.4. Recombinant
Vaccines
12.5.2.2.5. Other
Vaccines
12.5.2.3. The
UK Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.2.3.1. Rabies
12.5.2.3.2. Canine
Distemper Virus (CDV)
12.5.2.3.3. Canine
Parvovirus (CPV)
12.5.2.3.4. Canine Adenovirus (CAV)
12.5.2.3.5. Others
12.5.3. Spain
12.5.3.1. Spain
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.5.3.1.1. Beef
12.5.3.1.2. Equine
12.5.3.1.3. Dairy
12.5.3.1.4. Pork
12.5.3.1.5. Poultry
12.5.3.1.6. Sheep
12.5.3.1.7. Dog
12.5.3.1.8. Feline
12.5.3.1.9. Swine
12.5.3.1.10. Aquaculture
12.5.3.1.11. Ruminants
12.5.3.1.12. Others
12.5.3.2. Spain
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
12.5.3.2.1. Live
Attenuated Vaccines
12.5.3.2.2. Inactivated
Vaccines
12.5.3.2.3. Toxoid
Vaccines
12.5.3.2.4. Recombinant
Vaccines
12.5.3.2.5. Other
Vaccines
12.5.3.3. Spain
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.3.3.1. Rabies
12.5.3.3.2. Canine
Distemper Virus (CDV)
12.5.3.3.3. Canine
Parvovirus (CPV)
12.5.3.3.4. Canine Adenovirus (CAV)
12.5.3.3.5. Others
12.5.4. Germany
12.5.4.1. Germany
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.5.4.1.1. Beef
12.5.4.1.2. Equine
12.5.4.1.3. Dairy
12.5.4.1.4. Pork
12.5.4.1.5. Poultry
12.5.4.1.6. Sheep
12.5.4.1.7. Dog
12.5.4.1.8. Feline
12.5.4.1.9. Swine
12.5.4.1.10. Aquaculture
12.5.4.1.11. Ruminants
12.5.4.1.12. Others
12.5.4.2. Germany
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
12.5.4.2.1. Live
Attenuated Vaccines
12.5.4.2.2. Inactivated
Vaccines
12.5.4.2.3. Toxoid
Vaccines
12.5.4.2.4. Recombinant
Vaccines
12.5.4.2.5. Other
Vaccines
12.5.4.3. Germany
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.4.3.1. Rabies
12.5.4.3.2. Canine
Distemper Virus (CDV)
12.5.4.3.3. Canine
Parvovirus (CPV)
12.5.4.3.4. Canine Adenovirus (CAV)
12.5.4.3.5. Others
12.5.5. Italy
12.5.5.1. Italy
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.5.5.1.1. Beef
12.5.5.1.2. Equine
12.5.5.1.3. Dairy
12.5.5.1.4. Pork
12.5.5.1.5. Poultry
12.5.5.1.6. Sheep
12.5.5.1.7. Dog
12.5.5.1.8. Feline
12.5.5.1.9. Swine
12.5.5.1.10. Aquaculture
12.5.5.1.11. Ruminants
12.5.5.1.12. Others
12.5.5.2. Italy
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
12.5.5.2.1. Live
Attenuated Vaccines
12.5.5.2.2. Inactivated
Vaccines
12.5.5.2.3. Toxoid
Vaccines
12.5.5.2.4. Recombinant
Vaccines
12.5.5.2.5. Other
Vaccines
12.5.5.3. Italy
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.5.3.1. Rabies
12.5.5.3.2. Canine
Distemper Virus (CDV)
12.5.5.3.3. Canine
Parvovirus (CPV)
12.5.5.3.4. Canine Adenovirus (CAV)
12.5.5.3.5. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.5.6.1.1. Beef
12.5.6.1.2. Equine
12.5.6.1.3. Dairy
12.5.6.1.4. Pork
12.5.6.1.5. Poultry
12.5.6.1.6. Sheep
12.5.6.1.7. Dog
12.5.6.1.8. Feline
12.5.6.1.9. Swine
12.5.6.1.10. Aquaculture
12.5.6.1.11. Ruminants
12.5.6.1.12. Others
12.5.6.2. Nordic
Countries Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Technology
12.5.6.2.1. Live
Attenuated Vaccines
12.5.6.2.2. Inactivated
Vaccines
12.5.6.2.3. Toxoid
Vaccines
12.5.6.2.4. Recombinant
Vaccines
12.5.6.2.5. Other
Vaccines
12.5.6.3. Nordic
Countries Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
12.5.6.3.1. Rabies
12.5.6.3.2. Canine
Distemper Virus (CDV)
12.5.6.3.3. Canine
Parvovirus (CPV)
12.5.6.3.4. Canine Adenovirus (CAV)
12.5.6.3.5. Others
12.5.6.4. Nordic
Countries Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.5.7.1.1. Beef
12.5.7.1.2. Equine
12.5.7.1.3. Dairy
12.5.7.1.4. Pork
12.5.7.1.5. Poultry
12.5.7.1.6. Sheep
12.5.7.1.7. Dog
12.5.7.1.8. Feline
12.5.7.1.9. Swine
12.5.7.1.10. Aquaculture
12.5.7.1.11. Ruminants
12.5.7.1.12. Others
12.5.7.2. Benelux
Union Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
12.5.7.2.1. Live
Attenuated Vaccines
12.5.7.2.2. Inactivated
Vaccines
12.5.7.2.3. Toxoid
Vaccines
12.5.7.2.4. Recombinant
Vaccines
12.5.7.2.5. Other
Vaccines
12.5.7.3. Benelux
Union Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
12.5.7.3.1. Rabies
12.5.7.3.2. Canine
Distemper Virus (CDV)
12.5.7.3.3. Canine
Parvovirus (CPV)
12.5.7.3.4. Canine Adenovirus (CAV)
12.5.7.3.5. Others
12.5.7.4. Benelux
Union Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
12.5.8.1.1. Beef
12.5.8.1.2. Equine
12.5.8.1.3. Dairy
12.5.8.1.4. Pork
12.5.8.1.5. Poultry
12.5.8.1.6. Sheep
12.5.8.1.7. Dog
12.5.8.1.8. Feline
12.5.8.1.9. Swine
12.5.8.1.10. Aquaculture
12.5.8.1.11. Ruminants
12.5.8.1.12. Others
12.5.8.2. Rest
of Europe Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Technology
12.5.8.2.1. Live
Attenuated Vaccines
12.5.8.2.2. Inactivated
Vaccines
12.5.8.2.3. Toxoid
Vaccines
12.5.8.2.4. Recombinant
Vaccines
12.5.8.2.5. Other
Vaccines
12.5.8.3. Rest
of Europe Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
12.5.8.3.1. Rabies
12.5.8.3.2. Canine
Distemper Virus (CDV)
12.5.8.3.3. Canine
Parvovirus (CPV)
12.5.8.3.4. Canine Adenovirus (CAV)
12.5.8.3.5. Others
12.6. Key Segment
for Channeling Investments
12.6.1. By
Country
12.6.2. By Type
12.6.3. By
Technology
12.6.4. By
Disease Indication
13. Asia
Pacific Veterinary Vaccine Market Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Asia
Pacific Veterinary Vaccine Market Revenue (US$ Mn)
13.2. Asia
Pacific Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Beef
13.2.2. Equine
13.2.3. Dairy
13.2.4. Pork
13.2.5. Poultry
13.2.6. Sheep
13.2.7. Dog
13.2.8. Feline
13.2.9. Swine
13.2.10. Aquaculture
13.2.11. Ruminants
13.2.12. Others
13.3. Asia
Pacific Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
13.3.1. Live
Attenuated Vaccines
13.3.2. Inactivated
Vaccines
13.3.3. Toxoid
Vaccines
13.3.4. Recombinant
Vaccines
13.3.5. Other
Vaccines
13.4. Asia
Pacific Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.4.1. Rabies
13.4.2. Canine
Distemper Virus (CDV)
13.4.3. Canine
Parvovirus (CPV)
13.4.4. Canine Adenovirus (CAV)
13.4.5. Others
13.5. Asia
Pacific Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
13.5.1.1.1. Beef
13.5.1.1.2. Equine
13.5.1.1.3. Dairy
13.5.1.1.4. Pork
13.5.1.1.5. Poultry
13.5.1.1.6. Sheep
13.5.1.1.7. Dog
13.5.1.1.8. Feline
13.5.1.1.9. Swine
13.5.1.1.10. Aquaculture
13.5.1.1.11. Ruminants
13.5.1.1.12. Others
13.5.1.2. China
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
13.5.1.2.1. Live
Attenuated Vaccines
13.5.1.2.2. Inactivated
Vaccines
13.5.1.2.3. Toxoid
Vaccines
13.5.1.2.4. Recombinant
Vaccines
13.5.1.2.5. Other
Vaccines
13.5.1.3. China
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.1.3.1. Rabies
13.5.1.3.2. Canine
Distemper Virus (CDV)
13.5.1.3.3. Canine
Parvovirus (CPV)
13.5.1.3.4. Canine Adenovirus (CAV)
13.5.1.3.5. Others
13.5.2. Japan
13.5.2.1. Japan
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
13.5.2.1.1. Beef
13.5.2.1.2. Equine
13.5.2.1.3. Dairy
13.5.2.1.4. Pork
13.5.2.1.5. Poultry
13.5.2.1.6. Sheep
13.5.2.1.7. Dog
13.5.2.1.8. Feline
13.5.2.1.9. Swine
13.5.2.1.10. Aquaculture
13.5.2.1.11. Ruminants
13.5.2.1.12. Others
13.5.2.2. Japan
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
13.5.2.2.1. Live
Attenuated Vaccines
13.5.2.2.2. Inactivated
Vaccines
13.5.2.2.3. Toxoid
Vaccines
13.5.2.2.4. Recombinant
Vaccines
13.5.2.2.5. Other
Vaccines
13.5.2.3. Japan
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.2.3.1. Rabies
13.5.2.3.2. Canine
Distemper Virus (CDV)
13.5.2.3.3. Canine
Parvovirus (CPV)
13.5.2.3.4. Canine Adenovirus (CAV)
13.5.2.3.5. Others
13.5.3. India
13.5.3.1. India
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
13.5.3.1.1. Beef
13.5.3.1.2. Equine
13.5.3.1.3. Dairy
13.5.3.1.4. Pork
13.5.3.1.5. Poultry
13.5.3.1.6. Sheep
13.5.3.1.7. Dog
13.5.3.1.8. Feline
13.5.3.1.9. Swine
13.5.3.1.10. Aquaculture
13.5.3.1.11. Ruminants
13.5.3.1.12. Others
13.5.3.2. India
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
13.5.3.2.1. Live
Attenuated Vaccines
13.5.3.2.2. Inactivated
Vaccines
13.5.3.2.3. Toxoid
Vaccines
13.5.3.2.4. Recombinant
Vaccines
13.5.3.2.5. Other
Vaccines
13.5.3.3. India
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.3.3.1. Rabies
13.5.3.3.2. Canine
Distemper Virus (CDV)
13.5.3.3.3. Canine
Parvovirus (CPV)
13.5.3.3.4. Canine Adenovirus (CAV)
13.5.3.3.5. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
13.5.4.1.1. Beef
13.5.4.1.2. Equine
13.5.4.1.3. Dairy
13.5.4.1.4. Pork
13.5.4.1.5. Poultry
13.5.4.1.6. Sheep
13.5.4.1.7. Dog
13.5.4.1.8. Feline
13.5.4.1.9. Swine
13.5.4.1.10. Aquaculture
13.5.4.1.11. Ruminants
13.5.4.1.12. Others
13.5.4.2. New
Zealand Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
13.5.4.2.1. Live
Attenuated Vaccines
13.5.4.2.2. Inactivated
Vaccines
13.5.4.2.3. Toxoid
Vaccines
13.5.4.2.4. Recombinant
Vaccines
13.5.4.2.5. Other
Vaccines
13.5.4.3. New
Zealand Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.5.4.3.1. Rabies
13.5.4.3.2. Canine
Distemper Virus (CDV)
13.5.4.3.3. Canine
Parvovirus (CPV)
13.5.4.3.4. Canine Adenovirus (CAV)
13.5.4.3.5. Others
13.5.5. Australia
13.5.5.1. Australia
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
13.5.5.1.1. Beef
13.5.5.1.2. Equine
13.5.5.1.3. Dairy
13.5.5.1.4. Pork
13.5.5.1.5. Poultry
13.5.5.1.6. Sheep
13.5.5.1.7. Dog
13.5.5.1.8. Feline
13.5.5.1.9. Swine
13.5.5.1.10. Aquaculture
13.5.5.1.11. Ruminants
13.5.5.1.12. Others
13.5.5.2. Australia
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
13.5.5.2.1. Live
Attenuated Vaccines
13.5.5.2.2. Inactivated
Vaccines
13.5.5.2.3. Toxoid
Vaccines
13.5.5.2.4. Recombinant
Vaccines
13.5.5.2.5. Other
Vaccines
13.5.5.3. Australia
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.5.3.1. Rabies
13.5.5.3.2. Canine
Distemper Virus (CDV)
13.5.5.3.3. Canine
Parvovirus (CPV)
13.5.5.3.4. Canine Adenovirus (CAV)
13.5.5.3.5. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
13.5.6.1.1. Beef
13.5.6.1.2. Equine
13.5.6.1.3. Dairy
13.5.6.1.4. Pork
13.5.6.1.5. Poultry
13.5.6.1.6. Sheep
13.5.6.1.7. Dog
13.5.6.1.8. Feline
13.5.6.1.9. Swine
13.5.6.1.10. Aquaculture
13.5.6.1.11. Ruminants
13.5.6.1.12. Others
13.5.6.2. South
Korea Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
13.5.6.2.1. Live
Attenuated Vaccines
13.5.6.2.2. Inactivated
Vaccines
13.5.6.2.3. Toxoid
Vaccines
13.5.6.2.4. Recombinant
Vaccines
13.5.6.2.5. Other
Vaccines
13.5.6.3. South
Korea Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.5.6.3.1. Rabies
13.5.6.3.2. Canine
Distemper Virus (CDV)
13.5.6.3.3. Canine
Parvovirus (CPV)
13.5.6.3.4. Canine Adenovirus (CAV)
13.5.6.3.5. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
13.5.7.1.1. Beef
13.5.7.1.2. Equine
13.5.7.1.3. Dairy
13.5.7.1.4. Pork
13.5.7.1.5. Poultry
13.5.7.1.6. Sheep
13.5.7.1.7. Dog
13.5.7.1.8. Feline
13.5.7.1.9. Swine
13.5.7.1.10. Aquaculture
13.5.7.1.11. Ruminants
13.5.7.1.12. Others
13.5.7.2. Southeast
Asia Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
13.5.7.2.1. Live
Attenuated Vaccines
13.5.7.2.2. Inactivated
Vaccines
13.5.7.2.3. Toxoid
Vaccines
13.5.7.2.4. Recombinant
Vaccines
13.5.7.2.5. Other
Vaccines
13.5.7.3. Southeast
Asia Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.5.7.3.1. Rabies
13.5.7.3.2. Canine
Distemper Virus (CDV)
13.5.7.3.3. Canine
Parvovirus (CPV)
13.5.7.3.4. Canine Adenovirus (CAV)
13.5.7.3.5. Others
13.5.7.4. Southeast
Asia Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.8.1.1. Beef
13.5.8.1.2. Equine
13.5.8.1.3. Dairy
13.5.8.1.4. Pork
13.5.8.1.5. Poultry
13.5.8.1.6. Sheep
13.5.8.1.7. Dog
13.5.8.1.8. Feline
13.5.8.1.9. Swine
13.5.8.1.10. Aquaculture
13.5.8.1.11. Ruminants
13.5.8.1.12. Others
13.5.8.2. Rest
of Asia Pacific Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Technology
13.5.8.2.1. Live
Attenuated Vaccines
13.5.8.2.2. Inactivated
Vaccines
13.5.8.2.3. Toxoid
Vaccines
13.5.8.2.4. Recombinant
Vaccines
13.5.8.2.5. Other
Vaccines
13.5.8.3. Rest
of Asia Pacific Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
13.5.8.3.1. Rabies
13.5.8.3.2. Canine
Distemper Virus (CDV)
13.5.8.3.3. Canine
Parvovirus (CPV)
13.5.8.3.4. Canine Adenovirus (CAV)
13.5.8.3.5. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By Type
13.6.3. By Technology
13.6.4. By
Disease Indication
14. Middle
East and Africa Veterinary Vaccine Market Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Middle
East and Africa Veterinary Vaccine Market Revenue (US$ Mn)
14.2. Middle
East and Africa Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Type
14.2.1. Beef
14.2.2. Equine
14.2.3. Dairy
14.2.4. Pork
14.2.5. Poultry
14.2.6. Sheep
14.2.7. Dog
14.2.8. Feline
14.2.9. Swine
14.2.10. Aquaculture
14.2.11. Ruminants
14.2.12. Others
14.3. Middle
East and Africa Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Technology
14.3.1. Live
Attenuated Vaccines
14.3.2. Inactivated
Vaccines
14.3.3. Toxoid Vaccines
14.3.4. Recombinant
Vaccines
14.3.5. Other
Vaccines
14.4. Middle
East and Africa Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
14.4.1. Rabies
14.4.2. Canine
Distemper Virus (CDV)
14.4.3. Canine
Parvovirus (CPV)
14.4.4. Canine Adenovirus (CAV)
14.4.5. Others
14.5. Middle
East and Africa Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
14.5.1.1.1. Beef
14.5.1.1.2. Equine
14.5.1.1.3. Dairy
14.5.1.1.4. Pork
14.5.1.1.5. Poultry
14.5.1.1.6. Sheep
14.5.1.1.7. Dog
14.5.1.1.8. Feline
14.5.1.1.9. Swine
14.5.1.1.10. Aquaculture
14.5.1.1.11. Ruminants
14.5.1.1.12. Others
14.5.1.2. Saudi
Arabia Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
14.5.1.2.1. Live
Attenuated Vaccines
14.5.1.2.2. Inactivated
Vaccines
14.5.1.2.3. Toxoid
Vaccines
14.5.1.2.4. Recombinant
Vaccines
14.5.1.2.5. Other
Vaccines
14.5.1.3. Saudi
Arabia Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.5.1.3.1. Rabies
14.5.1.3.2. Canine
Distemper Virus (CDV)
14.5.1.3.3. Canine
Parvovirus (CPV)
14.5.1.3.4. Canine Adenovirus (CAV)
14.5.1.3.5. Others
14.5.2. UAE
14.5.2.1. UAE
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
14.5.2.1.1. Beef
14.5.2.1.2. Equine
14.5.2.1.3. Dairy
14.5.2.1.4. Pork
14.5.2.1.5. Poultry
14.5.2.1.6. Sheep
14.5.2.1.7. Dog
14.5.2.1.8. Feline
14.5.2.1.9. Swine
14.5.2.1.10. Aquaculture
14.5.2.1.11. Ruminants
14.5.2.1.12. Others
14.5.2.2. UAE
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
14.5.2.2.1. Live
Attenuated Vaccines
14.5.2.2.2. Inactivated
Vaccines
14.5.2.2.3. Toxoid
Vaccines
14.5.2.2.4. Recombinant
Vaccines
14.5.2.2.5. Other
Vaccines
14.5.2.3. UAE
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.2.3.1. Rabies
14.5.2.3.2. Canine
Distemper Virus (CDV)
14.5.2.3.3. Canine
Parvovirus (CPV)
14.5.2.3.4. Canine Adenovirus (CAV)
14.5.2.3.5. Others
14.5.3. Egypt
14.5.3.1. Egypt
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
14.5.3.1.1. Beef
14.5.3.1.2. Equine
14.5.3.1.3. Dairy
14.5.3.1.4. Pork
14.5.3.1.5. Poultry
14.5.3.1.6. Sheep
14.5.3.1.7. Dog
14.5.3.1.8. Feline
14.5.3.1.9. Swine
14.5.3.1.10. Aquaculture
14.5.3.1.11. Ruminants
14.5.3.1.12. Others
14.5.3.2. Egypt
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
14.5.3.2.1. Live
Attenuated Vaccines
14.5.3.2.2. Inactivated
Vaccines
14.5.3.2.3. Toxoid
Vaccines
14.5.3.2.4. Recombinant
Vaccines
14.5.3.2.5. Other
Vaccines
14.5.3.3. Egypt
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.3.3.1. Rabies
14.5.3.3.2. Canine
Distemper Virus (CDV)
14.5.3.3.3. Canine
Parvovirus (CPV)
14.5.3.3.4. Canine Adenovirus (CAV)
14.5.3.3.5. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
14.5.4.1.1. Beef
14.5.4.1.2. Equine
14.5.4.1.3. Dairy
14.5.4.1.4. Pork
14.5.4.1.5. Poultry
14.5.4.1.6. Sheep
14.5.4.1.7. Dog
14.5.4.1.8. Feline
14.5.4.1.9. Swine
14.5.4.1.10. Aquaculture
14.5.4.1.11. Ruminants
14.5.4.1.12. Others
14.5.4.2. Kuwait
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
14.5.4.2.1. Live
Attenuated Vaccines
14.5.4.2.2. Inactivated
Vaccines
14.5.4.2.3. Toxoid
Vaccines
14.5.4.2.4. Recombinant
Vaccines
14.5.4.2.5. Other
Vaccines
14.5.4.3. Kuwait
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.4.3.1. Rabies
14.5.4.3.2. Canine
Distemper Virus (CDV)
14.5.4.3.3. Canine
Parvovirus (CPV)
14.5.4.3.4. Canine Adenovirus (CAV)
14.5.4.3.5. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
14.5.5.1.1. Beef
14.5.5.1.2. Equine
14.5.5.1.3. Dairy
14.5.5.1.4. Pork
14.5.5.1.5. Poultry
14.5.5.1.6. Sheep
14.5.5.1.7. Dog
14.5.5.1.8. Feline
14.5.5.1.9. Swine
14.5.5.1.10. Aquaculture
14.5.5.1.11. Ruminants
14.5.5.1.12. Others
14.5.5.2. South
Africa Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
14.5.5.2.1. Live
Attenuated Vaccines
14.5.5.2.2. Inactivated
Vaccines
14.5.5.2.3. Toxoid
Vaccines
14.5.5.2.4. Recombinant
Vaccines
14.5.5.2.5. Other
Vaccines
14.5.5.3. South
Africa Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.5.5.3.1. Rabies
14.5.5.3.2. Canine
Distemper Virus (CDV)
14.5.5.3.3. Canine
Parvovirus (CPV)
14.5.5.3.4. Canine Adenovirus (CAV)
14.5.5.3.5. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Veterinary Vaccine Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.6.1.1. Beef
14.5.6.1.2. Equine
14.5.6.1.3. Dairy
14.5.6.1.4. Pork
14.5.6.1.5. Poultry
14.5.6.1.6. Sheep
14.5.6.1.7. Dog
14.5.6.1.8. Feline
14.5.6.1.9. Swine
14.5.6.1.10. Aquaculture
14.5.6.1.11. Ruminants
14.5.6.1.12. Others
14.5.6.2. Rest
of Middle East & Africa Veterinary Vaccine Market Revenue (US$ Mn) and
Forecasts, By Technology
14.5.6.2.1. Live
Attenuated Vaccines
14.5.6.2.2. Inactivated
Vaccines
14.5.6.2.3. Toxoid
Vaccines
14.5.6.2.4. Recombinant
Vaccines
14.5.6.2.5. Other
Vaccines
14.5.6.3. Rest
of Middle East & Africa Veterinary Vaccine Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.5.6.3.1. Rabies
14.5.6.3.2. Canine
Distemper Virus (CDV)
14.5.6.3.3. Canine
Parvovirus (CPV)
14.5.6.3.4. Canine Adenovirus (CAV)
14.5.6.3.5. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By Type
14.6.3. By
Technology
14.6.4. By
Disease Indication
15. Latin
America Veterinary Vaccine Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Latin
America Veterinary Vaccine Market Revenue (US$ Mn)
15.2. Latin
America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Beef
15.2.2. Equine
15.2.3. Dairy
15.2.4. Pork
15.2.5. Poultry
15.2.6. Sheep
15.2.7. Dog
15.2.8. Feline
15.2.9. Swine
15.2.10. Aquaculture
15.2.11. Ruminants
15.2.12. Others
15.3. Latin
America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
15.3.1. Live Attenuated
Vaccines
15.3.2. Inactivated
Vaccines
15.3.3. Toxoid
Vaccines
15.3.4. Recombinant
Vaccines
15.3.5. Other
Vaccines
15.4. Latin
America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.4.1. Rabies
15.4.2. Canine
Distemper Virus (CDV)
15.4.3. Canine
Parvovirus (CPV)
15.4.4. Canine Adenovirus (CAV)
15.4.5. Others
15.5. Latin
America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
15.5.1.1.1. Beef
15.5.1.1.2. Equine
15.5.1.1.3. Dairy
15.5.1.1.4. Pork
15.5.1.1.5. Poultry
15.5.1.1.6. Sheep
15.5.1.1.7. Dog
15.5.1.1.8. Feline
15.5.1.1.9. Swine
15.5.1.1.10. Aquaculture
15.5.1.1.11. Ruminants
15.5.1.1.12. Others
15.5.1.2. Brazil
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
15.5.1.2.1. Live
Attenuated Vaccines
15.5.1.2.2. Inactivated
Vaccines
15.5.1.2.3. Toxoid
Vaccines
15.5.1.2.4. Recombinant
Vaccines
15.5.1.2.5. Other
Vaccines
15.5.1.3. Brazil
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.5.1.3.1. Rabies
15.5.1.3.2. Canine
Distemper Virus (CDV)
15.5.1.3.3. Canine
Parvovirus (CPV)
15.5.1.3.4. Canine Adenovirus (CAV)
15.5.1.3.5. Others
15.5.2. Argentina
15.5.2.1. Argentina
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
15.5.2.1.1. Beef
15.5.2.1.2. Equine
15.5.2.1.3. Dairy
15.5.2.1.4. Pork
15.5.2.1.5. Poultry
15.5.2.1.6. Sheep
15.5.2.1.7. Dog
15.5.2.1.8. Feline
15.5.2.1.9. Swine
15.5.2.1.10. Aquaculture
15.5.2.1.11. Ruminants
15.5.2.1.12. Others
15.5.2.2. Argentina
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Technology
15.5.2.2.1. Live
Attenuated Vaccines
15.5.2.2.2. Inactivated
Vaccines
15.5.2.2.3. Toxoid
Vaccines
15.5.2.2.4. Recombinant
Vaccines
15.5.2.2.5. Other
Vaccines
15.5.2.3. Argentina
Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.5.2.3.1. Rabies
15.5.2.3.2. Canine
Distemper Virus (CDV)
15.5.2.3.3. Canine
Parvovirus (CPV)
15.5.2.3.4. Canine Adenovirus (CAV)
15.5.2.3.5. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By Type
15.5.3.1.1. Beef
15.5.3.1.2. Equine
15.5.3.1.3. Dairy
15.5.3.1.4. Pork
15.5.3.1.5. Poultry
15.5.3.1.6. Sheep
15.5.3.1.7. Dog
15.5.3.1.8. Feline
15.5.3.1.9. Swine
15.5.3.1.10. Aquaculture
15.5.3.1.11. Ruminants
15.5.3.1.12. Others
15.5.3.2. Rest
of Latin America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Technology
15.5.3.2.1. Live
Attenuated Vaccines
15.5.3.2.2. Inactivated
Vaccines
15.5.3.2.3. Toxoid
Vaccines
15.5.3.2.4. Recombinant
Vaccines
15.5.3.2.5. Other
Vaccines
15.5.3.3. Rest
of Latin America Veterinary Vaccine Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.5.3.3.1. Rabies
15.5.3.3.2. Canine
Distemper Virus (CDV)
15.5.3.3.3. Canine
Parvovirus (CPV)
15.5.3.3.4. Canine Adenovirus (CAV)
15.5.3.3.5. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By Type
15.6.3. By
Technology
15.6.4. By
Disease Indication
16. Competitive
Benchmarking
16.1. Market
Share Analysis, 2019
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player
Profiles
17.1. Aptimmune
Biologics Inc.
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Boehringer
Ingelheim International GmbH
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Brilliant
Bio Pharma Private Limited
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Ceva
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. China
Animal Husbandry
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Covetrus
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Elanco
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Hester
Biosciences Limited.
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Merck
& Co. Inc. (Intervet International B.V.)
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Torigen
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. VEROVACCiNES
GmbH
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Vetoquinol
S.A.
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. Virbac
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. Zoetis
17.14.1. Company
Details
17.14.2. Company
Overview
17.14.3. Product
Offerings
17.14.4. Key
Developments
17.14.5. Financial
Analysis
17.14.6. SWOT
Analysis
17.14.7. Business
Strategies
17.15. Other
Market Participants
18. Key
Findings
Note: This ToC is tentative and can
be changed according to the research study conducted during the course of
report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.